APR March 2024 - 33

« FORMULATION AND DEVELOPMENT
With so many developments taking place, one cannot help noticing
that these are not restricted to one or two regions. The US and Europe
are leading the way, but many Asian Pacific countries, including China,
Japan, Singapore, Korea, and India, are making tremendous efforts.
Challenges and Limitations
According to a Boston Consulting Group (BCG) analysis, in 2022, around
20 AI-intensive companies had 158 drug candidates in discovery
and preclinical development. Although
these
are noteworthy
developments, concerns are being raised that such developments
need further authentication. A study published in the journal Nature
states that these findings need to be reported in the peer-reviewed
literature and authenticated by researchers unaffiliated with the
companies involved.
Adding on, AI-based approaches typically require a large volume
of information for the AI models to be trained. In many cases, the
amount of data accessible may be limited, or the data may be of low
quality or inconsistent, which can affect the accuracy and reliability
of the results. Another challenge is the ethical consideration since AIbased
approaches may raise concerns about fairness and bias. If the
data used to train an ML algorithm is biased or unrepresentative, the
resulting predictions may not be accurate or fair.
Experts have also pointed out that even if AI does reduce the time
and cost involved in getting a compound into, and perhaps through,
preclinical testing, most drug candidates will still fail at later stages. But
anything that can speed up the process represents a win-win situation.
That is why the role of collaboration between AI researchers and
pharmaceutical scientists is crucial in the development of innovative
and effective treatments for various diseases. Both industry and
academia need to leverage each other's strengths to determine how
AI can be used to the best effect.
Another main point of AI implementation in drug discovery, or any
other application, is the apprehension of replacing humans, leading
to job loss. According to a recent report of 750 business leaders using
AI from ResumeBuilder, 37% say the technology replaced workers
in 2023. Meanwhile, 44% report that there will be layoffs in 2024
due to AI efficiency. While layoffs are a reality, AI technology is also
enabling business leaders to restructure and redefine the jobs we do.
Nevertheless, human intervention is mandatory for any AI platform's
successful implementation, development, and operation.
Future Perspectives
Amidst numerous challenges and limitations, the drug discovery
process requires compelling evidence for decision-making because it
directly affects public health. Nevertheless, the industry and academia
have demonstrated the benefits of drug discovery with AI technology
through their tremendous research work.
The immediate priority is to create AI technology tailored for drug
discovery to achieve meaningful progress. AI specialists must grasp
the nuances of drug discovery data and strive to create relevant and
transparent algorithms that elucidate the mechanisms of action,
thereby supporting informed decision-making.
Other domain experts will need to generate biological and chemical
data with minimal experimental errors and store them in unified
platforms for further improvements to the AI systems. Also, it will
be crucial for all stakeholders to be open to working together and
actively communicating to construct a concrete framework for a new
revolution in drug discovery.
www.americanpharmaceuticalreview.com |
| 33
»

http://www.americanpharmaceuticalreview.com

APR March 2024

Table of Contents for the Digital Edition of APR March 2024

Message from the Editor
Editorial Advisory Board
BIOPHARMACEUTICALS - Getting to GMP-Quality Biotherapeutics From Today’s Bench-Scale Continuous Manufacturing Systems: A Gap Analysis
MICROBIOLOGY - Critical Behavioral Attributes and the Application of COM-B Framework in Aseptic Processing
FORMULATION AND DEVELOPMENT - Use of AUC in AAV Analysis in a GMP Setting
FORMULATION AND DEVELOPMENT - Precision Medicine in Clinical Trials: A Statistical Perspective
An Interview with Dan Smithey, PhD President & CEO, Serán
FORMULATION AND DEVELOPMENT - Still Early Days for AI in Drug Discovery...Says Who?
QC Corner - Enhancing Material and Equipment Availability in Production Isolators
BIOPHARMACEUTICALS - Technologies for Aseptic Filling: The Choice is Clear
Vendor Viewpoint - Data Integrity and Rapid Micro Methods: Transforming to a Modern Microbiology Lab
MICROBIOLOGY - Bacterial Spore Formers in Disinfectant Efficacy Testing
Partner Perspective - Nanoparticle Technologies: Enablers for Ocular Drug Delivery
DRUG DELIVERY - Your Nails and You
DRUG DEVELOPMENT - Battling Exorbitance: High Costs in Sickle Cell Gene Therapies and the Imperative of Global Patient Registries for Equity
FORMULATION AND DEVELOPMENT - How Pharma Companies Are Solving Regulatory Challenges with AI-based Technology
Event Preview - CPHI North America
Event Preview - Excipient World 2024
P.I.N. Points
Advertiser's Index
APR March 2024 - CoverTip01
APR March 2024 - CoverTip02
APR March 2024 - Cover1
APR March 2024 - Cover2
APR March 2024 - 1
APR March 2024 - 2
APR March 2024 - 3
APR March 2024 - 4
APR March 2024 - 5
APR March 2024 - Message from the Editor
APR March 2024 - Editorial Advisory Board
APR March 2024 - BIOPHARMACEUTICALS - Getting to GMP-Quality Biotherapeutics From Today’s Bench-Scale Continuous Manufacturing Systems: A Gap Analysis
APR March 2024 - 9
APR March 2024 - 10
APR March 2024 - 11
APR March 2024 - 12
APR March 2024 - 13
APR March 2024 - MICROBIOLOGY - Critical Behavioral Attributes and the Application of COM-B Framework in Aseptic Processing
APR March 2024 - 15
APR March 2024 - 16
APR March 2024 - 17
APR March 2024 - 18
APR March 2024 - FORMULATION AND DEVELOPMENT - Use of AUC in AAV Analysis in a GMP Setting
APR March 2024 - 20
APR March 2024 - 21
APR March 2024 - 22
APR March 2024 - 23
APR March 2024 - FORMULATION AND DEVELOPMENT - Precision Medicine in Clinical Trials: A Statistical Perspective
APR March 2024 - 25
APR March 2024 - 26
APR March 2024 - 27
APR March 2024 - An Interview with Dan Smithey, PhD President & CEO, Serán
APR March 2024 - 29
APR March 2024 - 30
APR March 2024 - FORMULATION AND DEVELOPMENT - Still Early Days for AI in Drug Discovery...Says Who?
APR March 2024 - 32
APR March 2024 - 33
APR March 2024 - QC Corner - Enhancing Material and Equipment Availability in Production Isolators
APR March 2024 - 35
APR March 2024 - BIOPHARMACEUTICALS - Technologies for Aseptic Filling: The Choice is Clear
APR March 2024 - 37
APR March 2024 - 38
APR March 2024 - 39
APR March 2024 - Vendor Viewpoint - Data Integrity and Rapid Micro Methods: Transforming to a Modern Microbiology Lab
APR March 2024 - 41
APR March 2024 - MICROBIOLOGY - Bacterial Spore Formers in Disinfectant Efficacy Testing
APR March 2024 - 43
APR March 2024 - Partner Perspective - Nanoparticle Technologies: Enablers for Ocular Drug Delivery
APR March 2024 - 45
APR March 2024 - 46
APR March 2024 - 47
APR March 2024 - DRUG DELIVERY - Your Nails and You
APR March 2024 - 49
APR March 2024 - 50
APR March 2024 - 51
APR March 2024 - DRUG DEVELOPMENT - Battling Exorbitance: High Costs in Sickle Cell Gene Therapies and the Imperative of Global Patient Registries for Equity
APR March 2024 - 53
APR March 2024 - 54
APR March 2024 - 55
APR March 2024 - FORMULATION AND DEVELOPMENT - How Pharma Companies Are Solving Regulatory Challenges with AI-based Technology
APR March 2024 - 57
APR March 2024 - Event Preview - CPHI North America
APR March 2024 - 59
APR March 2024 - Event Preview - Excipient World 2024
APR March 2024 - 61
APR March 2024 - P.I.N. Points
APR March 2024 - 63
APR March 2024 - Advertiser's Index
APR March 2024 - Cover3
APR March 2024 - Cover4
https://www.nxtbookmedia.com